Author

Radhakrishnan P. Iyer

Spring Bank Pharmaceuticals (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Anjaneyulu Sheri· 1 shared Dillon C. ClearyiD· 1 shared Geeta Meher· 1 shared Rayomand H. Gimi· 1 shared Rupa Challa· 1 shared Santosh A. KhedkariD· 1 shared Seetharamaiyer Padmanabhan· 1 shared Shenghua ZhouiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Anjaneyulu Sheri

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

SB 11285, a Novel Canonical Purine-Pyrimidine Cyclic Dinucleotide, is a Systemically Bioavailable STING Agonist for Cancer Immunotherapy

Rupa Challa, Shenghua Zhou, Anjaneyulu Sheri, Geeta Meher, Seetharamaiyer Padmanabhan, Santosh A. Khedkar, Vishal Nair, Rayomand H. Gimi, Dillon C. Cleary, Radhakrishnan P. Iyer

This paper describes the development of SB 11285, a potent and bioavailable STING agonist showing antitumor activity in mouse models and undergoing clinical trials for cancer immunotherapy.

bioRxiv · Mar 27, 2025 · PreprintImmunology